Bank of America has revised its target price for Crispr Therapeutics (CRSP, Financial) from $79 to $78, maintaining a Buy rating on the stock. The adjustment comes as the firm slightly lowered its collaboration revenue projections for 2025 and 2026, due to delays in the cell collection process impacting revenue booking. Despite this, the firm remains optimistic about the company's potential product launch this year, according to an earnings preview focusing on small-to-mid cap biotech firms.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.80 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 23.67% from the current price of $65.33. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $36.68, suggesting a downside of 43.85% from the current price of $65.33. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
